Recorded Webinar: Artificial Intelligence Drug Discovery - Where are we now?

Webinar: Artificial Intelligence Drug Discovery - Where are we now?

Recorded live June 22, 2023

In the 1960s, pharmaceutical researchers started on a long journey to discover and develop new medicines using computers. These visionary scientists realized that humans assisted by computers could have a tremendous competitive advantage relative to traditional pencil and paper based approaches. Today, computational methods are now routinely used to extract value from the ever increasing volume and diversity of experimental data generated from highly interconnected multidisciplinary collaborators.

This webinar talks about the latest trends from drug discovery thought leaders in the industry using AI to model and predict medicinal and biological properties.

Speaker includes...

Matthew Segall, PhD

CEO at Optibrium Ltd

Matt Segall is the CEO of Optibrium Ltd, which provides integrative, intuitive software for small molecule design, optimisation and data analysis. From advanced artificial intelligence technologies to user-friendly drug design platforms, such as StarDrop™ and Cerella™, all Optibrium products and services are backed up by rigorous scientific research and support scientists in their decision making throughout the drug discovery process.

Dr. Segall has a Masters of Science in Computation from the University of Oxford and a PhD in Theoretical Physics from the University of Cambridge.

Hanjo Kim, PhD

SVP Strategic Planning at Standigm

Hanjo Kim is a Senior Vice President at Standigm, an AI drug discovery company with operations in Seoul (South Korea), Cambridge (UK), and Cambridge (USA). At Standigm, he has held multiple roles, including SVP of Global Strategy, Head of Medicinal Chemistry and Deputy Head of Research. 

Dr. Kim received a Bachelor of Science in Chemistry, Masters of Science and PhD in Organic Chemistry degrees from Yonsei University in Korea.

Alpha Lee, PhD

Co-founder & CSO at PostEra

Alpha Lee is the Co-founder and Chief Scientific Officer of PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery. The company focuses on using advances in machine learning to close the Design-Make-Test cycle of Medicinal Chemistry.

Dr. Lee has a Bachelor of Science in Chemistry from Imperial College London and Masters of Mathematical Modeling and Scientific Computing and PhD degrees from University of Oxford.